文献速递乳腺癌

Durvalumab联合新辅助化疗治疗早期三阴性乳腺癌:GeparNuevo试验长期分析

Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial.
PubMed 文献 · J Clin Oncol · 2026-04-20

中位随访86.4个月,Durvalumab组较安慰剂组持续显著改善iDFS、DDFS和OS,且无论病理缓解程度如何均获益。

要点

  • Durvalumab联合新辅助化疗显著改善长期iDFS、DDFS和OS。
  • 获益不受病理缓解程度影响,提示需重新评估辅助免疫治疗延续的必要性。
  • 基线有淋巴结受累患者iDFS获益更明显,残留病灶sTILs高者7年iDFS率更高。

核心结论

  • 在新辅助化疗中加入Durvalumab而不进行辅助免疫检查点抑制剂延续,可改善早期三阴性乳腺癌患者的长期生存结局,且不论病理缓解程度如何。

主要发现

  • 残留病灶中sTILs高(>10%)者7年iDFS率为92.3%(95%CI 56.6-98.9),低者(≤10%)为51.4%(95%CI 29.2-69.7)。

临床怎么用

  • 对于早期三阴性乳腺癌,新辅助化疗联合Durvalumab可考虑用于改善长期生存,但辅助免疫治疗延续的必要性需进一步研究。

局限性

  • 为II期试验,样本量有限;残留病灶sTILs分析仅纳入39/71例未达pCR的患者,属探索性事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase II GeparNuevo trial investigated whether adding durvalumab to neoadjuvant chemotherapy (NACT) only in patients with early triple-negative breast cancer cT1b-cT4a-d would improve pathologic complete response (pCR) rate and patient survival. Hundred and seventy-four patients were randomly assigned to receive durvalumab or placebo concurrently with nab-paclitaxel once per week and followed by dose-dense epirubicin and cyclophosphamide. With 86.4 months of median follow-up compared with the previously reported 43.7 months, durvalumab showed sustained significant improvements in long-term outcomes as defined by STEEP compared with placebo regarding not only invasive disease-free survival (iDFS; hazard ratio [HR], 0.56 [95% CI, 0.32 to 0.99]; stratified log-rank P = .0431), but also distant disease-free survival (DDFS; HR, 0.41 [95% CI, 0.21 to 0.80]; P = .0069) and overall survival (OS; HR, 0.33 [95% CI, 0.14 to 0.79]; P = .0085). All analyses were stratified by stromal tumor-infiltrating lymphocytes (sTILs) at baseline (low [≤10%], intermediate [11%-59%], high [≥60%]). In exploratory subgroup analysis, patients with nodal involvement at baseline demonstrated a greater iDFS benefit (HR, 0.33 [95% CI, 0.144 to 0.771]; P = .01; Pinteraction = 0.045). sTILs in residual disease (RD) could be assessed in 39/71 patients without pCR. Post hoc analyses by sTILs high (>10%) versus low (≤10%) in RD showed estimated 7-year iDFS rates of 92.3% (95% CI, 56.6 to 98.9) and 51.4% (95% CI, 29.2 to 69.7), respectively. Hence, adding durvalumab to dose-dense NACT without adjuvant continuation of checkpoint inhibition improved long-term survival outcomes, irrespective of the extent of pathologic response. This underscores the necessity to re-evaluate the adjuvant continuation of checkpoint inhibition.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Loibl S, Untch M, Huober J, et al. Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial. J Clin Oncol. 2026. PMID: 42008768. doi:10.1200/JCO-25-02311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。